---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-017220"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:59:13.129467+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q2 net loss $25.6M, cash $207M; stops PYX-202, prioritizes two lead programs

## Summary
- Cash $207M as of Aug 15, 2022; expected to fund operations through second half of 2024.
- Q2 net loss $25.6M ($0.79/sh) vs $8.1M ($5.54/sh) in 2021; R&D expense $17.2M (from $3.2M).
- Prioritizes PYX-201 (anti-EDB ADC) and PYX-106 (anti-Siglec-15 mAb) for IND filings in H2 2022.
- Ceases development of PYX-202 (anti-DLK1 ADC) after toxicology data; pauses PYX-203 and PYX-102.
- Appoints Dr. Rachel Humphrey to Board; receives option grant for 236,220 shares at $2.91.

## SEC filing metadata
- accession: 0000950170-22-017220
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017022017220/0000950170-22-017220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017022017220/pyxs-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-017220
- JSON: https://secwatch.observer/filing/0000950170-22-017220.json
- Plain text: https://secwatch.observer/filing/0000950170-22-017220.txt

## Key facts
- Executive change
  Rachel Humphrey was appointed as Director at Pyxis Oncology, Inc..
  - Action: appointed
  - Role: Director
  source text: On August 11, 2022, Pyxis Oncology, Inc. appointed Rachel Humphrey, M.D., to its Board of Directors and to serve on the Board’s Nominating and Corporate Governance Committee and Compensation Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017022017220/0000950170-22-017220-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.